This is a news story, published by Good News Network, that relates primarily to NSCLC news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Good News Network, you can click here:
more news from Good News NetworkOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
lung cancers. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Cancer Cells news, cancer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lung cancerGood News Network
•75% Informative
Five-year results of a phase III trial present the longest progression-free survival data ever reported when treating non-small cell lung cancer ( NSCLC ) with a single targeted intervention.
Called lorlatinib, the drug is from a class of pioneering medications known as anaplastic lymphoma kinase inhibitors.
VR Score
66
Informative language
60
Neutral language
31
Article tone
formal
Language
English
Language complexity
67
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
7
Source diversity
4
Affiliate links
no affiliate links